AXQ Capital LP Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AXQ Capital LP trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 69.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 382 shares of the biopharmaceutical company’s stock after selling 873 shares during the quarter. AXQ Capital LP’s holdings in Regeneron Pharmaceuticals were worth $272,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of REGN. Raymond James Trust N.A. boosted its stake in Regeneron Pharmaceuticals by 2.9% during the third quarter. Raymond James Trust N.A. now owns 1,064 shares of the biopharmaceutical company’s stock worth $1,119,000 after buying an additional 30 shares during the period. Meridian Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 5.7% during the third quarter. Meridian Wealth Management LLC now owns 1,019 shares of the biopharmaceutical company’s stock valued at $1,071,000 after purchasing an additional 55 shares during the period. Great Valley Advisor Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 5.0% during the third quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company’s stock valued at $465,000 after purchasing an additional 21 shares during the period. Cerity Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 18.5% during the third quarter. Cerity Partners LLC now owns 15,548 shares of the biopharmaceutical company’s stock valued at $16,344,000 after purchasing an additional 2,423 shares during the period. Finally, Kingsview Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.6% during the third quarter. Kingsview Wealth Management LLC now owns 860 shares of the biopharmaceutical company’s stock valued at $904,000 after purchasing an additional 22 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. TD Cowen lowered their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Bank of America reissued an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Finally, Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $658.48 on Monday. The firm has a market cap of $71.99 billion, a price-to-earnings ratio of 17.20, a PEG ratio of 2.34 and a beta of 0.27. The firm has a 50-day simple moving average of $689.43 and a two-hundred day simple moving average of $813.15. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $11.86 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.